Katerina Chatzidionysiou

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.6K citations · Full text

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Ronald van Vollenhoven, Pierre Geborek, Kristina Forslind et al. · The Lancet · 2012 · 223 citations

Rheumatoid Disorder, Rheumatology, Systemic Treatment +8

Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study

Hannah Bower, Thomas Frisell, Daniela Di Giuseppe et al. · Annals of the Rheumatic Diseases · 2021 · 101 citations · Full text

The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries

Delphine S. Courvoisier, Katerina Chatzidionysiou, Denis Mongin et al. · Lara D. Veeken · 2020 · 90 citations

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

Katerina Chatzidionysiou, Elisabeth Lie, E L Nasonov et al. · Annals of the Rheumatic Diseases · 2011 · 76 citations · Full text